Archives March 2026

Strengthening its commitment to sustainable living, AAS NGO has announced the launch of its third “AAS Bartan Bank,” expanding its community-driven initiative aimed at reducing disposable waste generated during social gatherings and celebrations.

India generates over 62 million tonnes of waste annually, a significant share of which comes from single-use plastics and disposable items widely used at events. From weddings to small household functions, a single gathering can generate hundreds to thousands of disposable plates, cups, and cutlery within hours—most of which end up in landfills or polluting the environment.

The AAS Bartan Bank offers a practical and impactful solution. Individuals hosting events can borrow reusable utensils, use them, and return them after cleaning—completely free of cost. By making sustainable alternatives both accessible and convenient, the initiative encourages a meaningful shift away from single-use consumption.

A key highlight of the initiative is its community-based deployment model. Bartan Banks are being established across RWAs, temples, gurudwaras, and other community spaces, ensuring easy access for residents within their neighborhoods. The launch of the third Bartan Bank marks an important milestone in scaling this grassroots effort and deepening its community reach.

Speaking on the initiative, Varsha Goel, Founder President of AAS NGO, said, “Every celebration should leave behind memories, not waste. With the launch of our third AAS Bartan Bank, we are taking another step towards making sustainable celebrations the norm rather than the exception.”

The initiative holds particular relevance in Delhi, where waste management continues to be a critical challenge. The city generates over 11,800 tonnes of municipal solid waste daily, with a substantial portion ending up in landfills such as Okhla, Ghazipur, and Bhalswa—posing serious environmental and public health concerns. Disposable waste from events remains a key contributor to this burden.

By promoting reusable alternatives, the Bartan Bank addresses waste at its source, helping reduce pressure on already overburdened landfill systems.

Adding to this, Virendra Kumar Goel, Convener, AAS NGO, said, “The launch of our third Bartan Bank reflects the growing acceptance of this initiative among communities. Real change happens when people come together, and this model empowers citizens to become part of the solution.”

As sustainability awareness continues to grow, AAS NGO’s expanding Bartan Bank network stands as a compelling example of how community-led initiatives can drive scalable, meaningful change—redefining celebrations while protecting the environment.

George Stallworth and Ashley Thornton bring accounting and customer service expertise to the growing nonprofit.

(St. Louis, Mo., March 26, 2026) Child Care Aware of Missouri (CCAMO) recently welcomed two new team members as the nonprofit continues to strengthen operations and enhance support for families and child care providers across the state.

George Stallworth has joined CCAMO as Accounting Specialist, managing a range of accounting and financial activities. He will ensure the accuracy of financial reporting while supporting the organization’s budgeting and fiscal management processes. Stallworth brings extensive experience from roles with the Salvation Army and Advantage 2000. A U.S. Navy Logistics Specialist School graduate, he holds a Bachelor of Science degrees in both Accountancy and Business Administration from Southern Illinois University Edwardsville.

Ashley Thornton has been named Assistant Director of Customer Service Experiences, a newly created position designed to lead day-to-day call center operations and provide strategic direction for CCAMO’s offsite customer support team. Thornton previously served as a Call Center Supervisor for Keefe Group. She earned her Bachelor of Arts degree in Psychological Sciences from the University of Missouri-St. Louis.

“We are thrilled to welcome George and Ashley to our growing team,” said CCAMO CEO Robin Phillips. “Their expertise in accounting and customer service strengthens our ability to serve families, child care providers, and community partners with excellence. Each brings a passion for helping others and a commitment to our mission of ensuring that every child in Missouri has access to quality care.”

Founded in 1999, CCAMO is a statewide nonprofit that focuses on a comprehensive early childhood education experience through impactful programs and partnerships. The organization’s services include workforce development, child care business supports, advocacy and policy work, and its new Child Care Keeps Missouri Working, a regional campaign offering concierge solutions to businesses undergoing employee recruitment and retention challenges due to the overwhelming shortage of quality child care options. For more information, call (314) 535-1458 or visit www.mochildcareaware.org.

15-minute pretreatment enables recovery of metals and graphite from spent lithium-ion batteries

HOUSTON, TX (March 26, 2026) – Critical minerals such as those used in lithium-ion batteries come in limited supply and are concentrated in specific regions around the world. Securing a reliable supply of these materials is a priority for governments worldwide, yet most spent batteries end up in landfills, leeching toxic chemicals into the environment.

“Recycling waste batteries is the most practical solution for tackling this strained supply chain, but studies show that that happens with less than 10% of battery waste,” said Gautam Chandrasekhar, a doctoral student in the materials science and nanoengineering department at Rice University who is a first author on a study pioneering a new battery recycling method.

The researchers used a brief microwave-induced plasma treatment to recover nearly all of the valuable metals in battery waste using room-temperature, comparatively mild solvents, including citric acid. The process also regenerated graphite — the main material in a battery’s anode.

“With plasma pretreatment, almost 95% of metals, including lithium, can be recovered from battery black mass using nothing harsher than the acid found in a lemon,” said Chandrasekhar, who is part of Pulickel Ajayan’s research group at Rice.

Current recycling protocols involve shredding battery waste down to a substance known as black mass, which contains minerals such as lithium, cobalt, nickel, graphite, manganese, aluminum and more. Processing black mass for mineral extraction typically requires energy-intensive industrial processes involving high temperatures and strong acids, and recovery rates are uneven.

“Industrial battery recycling processes in use today have very low metal extraction efficiency and focus mostly on the cathode,” said Xiang Zhang, assistant research professor at Rice and a co-first author on the study.

Lithium can be particularly difficult to capture efficiently, and graphite — which makes up roughly 22% of the battery’s weight — is rarely returned to batteries because it gets damaged during conventional recycling processes.

“This is one of the most important things to note regarding battery recycling: As the single most voluminous component in lithium-ion batteries, graphite remains almost irreplaceable as anode in widespread commercial battery applications,” said Sohini Bhattacharyya, a research scientist in the Ajayan group who is a corresponding author on the study.

Bhattacharyya said the goal of the research was to develop a one-step pretreatment process for battery recycling that could be added onto existing industrial processes to improve efficiency and reduce environmental impacts while recovering “all critical materials, including graphite.”

“We hypothesized that using microwave-induced plasma to break down the metal oxide particles as a pretreatment step would make their hydrometallurgical recovery in weaker acids easier,” Bhattacharyya said.

To test their hypothesis, the team used a custom microwave plasma reactor built by Zhang. After exposing black mass to microwave-induced plasma — an energized gas of charged particles — for 15 minutes, more than 90% of all metals were recovered in a citric acid bath at room temperature, while lithium was selectively recovered in water. Moreover, the treatment was found to remove residues and structural defects that accumulate on graphite during battery use.

“The recovered graphite shows excellent performance as an anode when reintroduced in a battery,” Chandrasekhar said.

The technology has been patented, and the team is moving toward commercialization. Early technoeconomic analysis suggests the process could outperform current industrial methods, particularly by recovering graphite in a form suitable for reuse in batteries.

“This is a breakthrough methodology for recovering all critical minerals from battery black mass with minimal chemical and energy usage,” said Ajayan, Rice’s Benjamin M. and Mary Greenwood Anderson Professor of Engineering and professor of materials science and nanoengineering.

MISATO, JAPAN – 26 March 2026 – Zuellig Pharma today announced the successful relocation of its new clinical depot to Misato, strengthening its ability to deliver global quality standards with local operational agility and further strengthening its clinical supply capability across Asia Pacific. Japan remains one of the region’s preferred locations for clinical research, underpinned by its strong focus on medical advancement, rigorous ethical standards and commitment to healthcare.

Medical innovation across the region continues to accelerate, with China, India, Australia, Japan, South Korea, Taiwan and Singapore emerging as key pillars of Asia Pacific’s clinical trial ecosystem over the past five years^[1]. Against this backdrop, the move in Japan reinforces Zuellig Pharma’s commitment to supporting sponsors and clients with reliable, compliant and seamless access to Japan – advancing its broader mission to make healthcare more accessible.

The new depot will bring together Zuellig Pharma’s established knowledge assets, operational excellence, and clinical logistics and sourcing expertise. Backed by a highly experienced and expert-led local team, the depot delivers precision project management tailored to Japan’s intricate regulatory and logistical requirements, while enabling smoother coordination for multi-market studies as the clinical landscape continues to evolve.

“As sponsors and clients increasingly run multi-market studies, they need clinical supply partners that can deliver consistency across borders while navigating local complexity,” said John Graham, Chief Executive Officer, Zuellig Pharma. “This relocated depot will strengthen access to Japan within our regional network, helping us execute with greater reliability, compliance, and speed across the region.”

The Misato clinical depot will also provide a streamlined, turnkey solution for global sponsors seeking rapid and compliant market entry into Japan. Sponsors will benefit from the same rigorous operational excellence, regulatory adherence, and service consistency delivered by Zuellig Pharma’s strategic network of clinical depots, without the overhead of building or managing costly standalone facilities. This milestone supports Zuellig Pharma’s ongoing efforts to accelerate clinical development and improve patient access to innovative therapies across Asia Pacific.

With this strategic move, Zuellig Pharma further strengthens its position as a trusted partner for global clinical development, combining scale, expertise, and agility whilst delivering high-quality, compliant clinical logistics and sourcing solutions across Asia Pacific.

The report highlights a broader shift towards more connected manufacturing systems 

PORTO, Portugal, 25.03.2026 – Critical Manufacturing, the Industrial Operations Platform company that unites execution, connectivity, analytics and trusted AI, and a subsidiary of ASMPT, has been named a Representative Vendor in the Gartner Market Guide for Manufacturing Execution Systems (MES). The report points to the continued shift in manufacturing systems toward more connected and data-driven models as operational requirements grow, with increasing focus on the role of AI and more open, interoperable approaches to managing production systems.

According to Gartner, MES remains central to digital manufacturing, with vendors evolving their offerings to meet changing business and production needs, including greater emphasis on integration, flexibility, and platform-based capabilities.

Francisco Almada Lobo, CEO and Co-founder of Critical Manufacturing, said, “We are pleased to be recognized in the Gartner Market Guide for MES. In our opinion this reflects our continued focus on helping manufacturers succeed in highly demanding and regulated industries now and in the future. We continue to evolve our solution embedding the latest technologies such as AI on a strong foundation that manufacturers can trust to make digital transformation effective and profitable.”

As manufacturing becomes more intricate, organizations are placing greater emphasis on how their systems improve visibility, coordination, and decision-making. Critical Manufacturing addresses these needs through its Industrial Operations Platform approach, where MES serves as the execution core within a broader framework that brings together production, data, and intelligence.

“Manufacturing is no longer just about controlling processes on the shopfloor. It is about turning production data into meaningful, timely decisions that improve performance across the entire operation,” added Almada Lobo. “We are seeing a clear shift away from isolated systems toward environments where execution, data, and intelligence continuously inform each other. That is what enables manufacturers to respond faster, operate with greater clarity, and remain competitive in increasingly complex markets.”

Within this approach, MES plays a central role in capturing and contextualizing manufacturing data, which is then linked with analytics and enterprise systems to create a continuous flow of information between the shopfloor and business decision-makers.

Critical Manufacturing continues to advance its solution for high-tech industries such as semiconductors, electronics, medical devices and life sciences, and industrial equipment. Recent enhancements include improved batch management with lot matching, resource cluster services for multi-chamber equipment, and more detailed labor tracking at the activity level. Additional capabilities such as flexible BOM management, advanced substrate mapping, and smart barcode scanning further strengthen control and traceability across manufacturing processes.

The platform has also been extended with improvements to line clearance and maintenance management for reusable spare parts, alongside new reporting capabilities through tools such as Grafana and Stimulsoft. The introduction of Unified Namespace streaming via MQTT, combined with a centralized enterprise data platform, provides broader visibility across multiple sites.

At the same time, Critical Manufacturing is advancing its AI roadmap through initiatives spanning machine learning and generative AI to more advanced autonomous systems. These capabilities are embedded within the MES and data platform to enable contextual understanding, predictive insights, and more efficient workflows for both operators and decision-makers.

The report also encourages manufacturers to assess how MES solutions will meet future needs, including integration with other systems, responsiveness to changing processes, and the ability to scale across sites. For organizations operating in complex sectors, selecting solutions aligned with specific operational requirements can help reduce implementation effort while preserving long-term flexibility.

With customers across APAC, EMEA, and North America, Critical Manufacturing works with manufacturers in sectors where traceability, quality, and responsiveness are essential. By bringing together MES, data, analytics, and AI within a unified platform, the company helps manufacturers build more resilient, transparent, agile and future-ready operations.

Gartner disclaimer

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner is a trademark of Gartner, Inc., and/or its affiliates.

Munich, Germany – 25 March 2026: Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapies for complement-mediated diseases, today announced that the first patient has been dosed in Opti-GAIN, its first-in-human Phase I/II clinical trial evaluating CTx001 in patients with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).

Opti-GAIN is a multi-centre Phase I/II study designed to assess the safety, tolerability, and preliminary efficacy of CTx001, administered via a single subretinal injection. Part 1 of the study is an open-label, dose-escalation phase across three cohorts, followed by a dose-expansion phase in Part 2. The trial is being conducted by the company’s UK subsidiary.

“Geographic Atrophy remains an area of significant unmet need, with patients facing progressive and irreversible vision loss,” said Dr. Arshad M. Khanani, Chief Investigator of the study and Director of Clinical Research at Sierra Eye Associates, Reno, Nevada, USA. “I am pleased to be part of this first-in-human trial and to have administered CTx001 to the first patient. We look forward to further evaluating this promising one-time investigational gene therapy approach in GA secondary to AMD.”

CTx001 is an investigational AAV2-based gene therapy engineered to deliver a construct encoding mini-CR1, a truncated and secreted form of Complement Receptor 1. This approach is designed to modulate both the alternative and classical complement pathways. Subretinal administration enables local production of mini-CR1 within retinal cells, while its small size may facilitate penetration across Bruch’s membrane, supporting broad ocular biodistribution, including the choriocapillaris.

Building on clinically validated complement biology in GA, CTx001 aims to deliver a potentially best-in-class profile, combining broad ocular coverage, strong potency, multi-pathway modulation, and extended durability.

The Opti-GAIN trial is being conducted alongside Pre-GAIN, the company’s ongoing natural history study in GA, currently enrolling patients in both the United States and the United Kingdom. Together, these studies are expected to inform patient selection and enable the evaluation of novel structural and functional endpoints, including ellipsoid zone (EZ) integrity and focal Optical Coherence Tomography (OCT)-based microperimetry. Notably, Opti-GAIN is among the first clinical studies to prospectively evaluate focal OCT-based microperimetry, a method that could significantly advance treatment assessment in GA.

“Dosing the first patient in Opti-GAIN marks a key milestone for Complement Therapeutics and the clinical development of CTx001,” said Dr. Rafiq Hasan, Chief Executive Officer of Complement Therapeutics. “We believe our differentiated gene therapy approach, combined with an integrated clinical strategy, positions CTx001 strongly. Running Opti-GAIN alongside Pre-GAIN enables us to generate both interventional and natural history data to better guide patient selection, endpoint development, and future trials.”

Dr. Muhammad Ali Memon, Chief Medical Officer of Complement Therapeutics, added: “Our precise surgical delivery approach, adaptive immunomodulatory regimen, and well-characterised patient populations from i-GAIN and Pre-GAIN provide a strong foundation for demonstrating therapeutic impact with CTx001 in Opti-GAIN.”

Further details on the company’s clinical programmes are available on ClinicalTrials.gov, including Opti-GAIN (NCT07392255) and Pre-GAIN (NCT07144137).